Biolife Sciences (Biolife Sciences) EBIT : $-0.12 Mil (TTM As of May. 2008)

View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences EBIT?

Biolife Sciences's earnings before interest and taxes (EBIT) for the three months ended in May. 2008 was $0.08 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in May. 2008 was $-0.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biolife Sciences's annualized ROC % for the quarter that ended in May. 2008 was 6.91%. Biolife Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in May. 2008 was 407.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biolife Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2008 was -36.79%.

Biolife Sciences EBIT Historical Data

The historical data trend for Biolife Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences EBIT Chart

Biolife Sciences Annual Data

Trend

Nov04

Nov05

Nov06

Nov07

EBIT

-0.02

-0.53

0.02

0.04

Biolife Sciences Quarterly Data
	Nov04	Feb05	May05	Aug05	Nov05	Feb06	May06	Aug06	Nov06	Feb07	May07	Aug07	Nov07	Feb08	May08
EBIT	Get a 7-Day Free Trial										0.16	0.01	-0.10	-0.11	0.08

Competitive Comparison of Biolife Sciences's EBIT

For the Medical Instruments & Supplies subindustry, Biolife Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolife Sciences's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolife Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biolife Sciences's EV-to-EBIT falls into.

Biolife Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in May. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

Biolife Sciences (OTCPK:BLFE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biolife Sciences's annualized ROC % for the quarter that ended in May. 2008 is calculated as:

	ROC % (Q: May. 2008 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Feb. 2008 )	+	Invested Capital (Q: May. 2008 ))	/ count )
=	0.336 * ( 1 - 0% )	/	( (4.834	+	4.89)	/ 2 )
=	0.336	/	4.862
=	6.91 %

where

	Invested Capital		(Q: Feb. 2008 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.174	-	0.647	-	( 0.02	-	max(0, 3.206	-	0.899	+	0.02	))
=	4.834

	Invested Capital		(Q: May. 2008 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.041	-	0.434	-	( 0.04	-	max(0, 3.038	-	0.755	+	0.04	))
=	4.89

Note: The Operating Income data used here is four times the quarterly (May. 2008) data.

2. Joel Greenblatt's definition of Return on Capital:

Biolife Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in May. 2008 is calculated as:

	ROC (Joel Greenblatt) %		(Q: May. 2008 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Feb. 2008		Q: May. 2008
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0.336	/	( ( (0.086 + max(-0.188, 0))	+	(0.079 + max(-0.062, 0)) )	/	2 )
=	0.336	/	( ( 0.086	+	0.079 )	/	2 )
=	0.336	/	0.0825
=	407.27 %

where Working Capital is:

	Working Capital		(Q: Feb. 2008 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.164	+	0	+	0.521)	-	(0.647	+	0	+	0.226)
=	-0.188

	Working Capital		(Q: May. 2008 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.143	+	0	+	0.396)	-	(0.434	+	0	+	0.167)
=	-0.062

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (May. 2008) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biolife Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: May. 2008 )
	=	-0.117	/	0.318
	=	-36.79 %

Biolife Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolife Sciences (Biolife Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052

Website

https://www.biolifesciences.com

Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.

Executives

Arthur Viola

director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired • 09-15-2020